SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Qualified Opinion who wrote (3285)9/30/2002 6:40:53 PM
From: Icebrg  Read Replies (1) of 10345
 
Rob, you suggested:

>>Hospital drugs should be part of asset divestiture and excluded from product revenue>>

If that is indeed the fact the situation is not as bleak as it might look.

But, while there is a reference in the press release to a loss of revenue due to the asset disposal program, I doubt that it refers to the hospital products. The hospital products represent such a large part of the turnover (60 mUSD in Q2) that if they were not included in the reported figures Elan would and should have pointed that out. (It is much better to have 40 mUSD of unspecified revenue losses than 100 mUSD).

Ice
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News